Fresenius

Fresenius is one of the top 40 companies in Germany in terms of market capitalization and is included in Germany's leading index, the DAX. We are also listed in the STOXX Europe 600 Health Care, the FTSEurofirst 300 and the DAXsector Pharma & Healthcare indices.

Fresenius ordinary shares are traded on the stock exchanges in Frankfurt, Düsseldorf and Munich.

At the end of July 2022, Fresenius SE & Co. KGaA's capital stock was 563,237,277 ordinary shares. The shares are notional no-par-value shares. Each share represents €1.00 of the capital stock.

 

Basic Share information

Ordinary share

Securities identification no.

578 560

Ticker symbol

FRE

ISIN

DE0005785604

Bloomberg symbol

FRE GR

Reuters symbol

FREG.de

Main trading location

Frankfurt/Xetra

Paying agent

Deutsche Bank AG, Taunusanlage 12, 60325 Frankfurt am Main, Germany

Key data

2024 2023 2022

Numbers of shares

563,237,277  563,237,277  563,237,277

Stock exchange quotation1 in € 

High

 34.85  31.11  37.88

Low

 24.54  23.46  20.04

Year-end quotation

 33.54  28.07  26.25

Market capitalization2 in million €

 18,891  15,810  14,785

Total dividend distribution in million €

 5633  -  518

Dividend per share in €

1.003 -  0.92

Earnings per share in €4 

 3.11  2.67  3.08

    • 1 Xetra closing price on the Frankfurt Stock Exchange
    • 2 Total number of ordinary shares multiplied by the respective Xetra year-end quotation on the Frankfurt Stock Exchange
    • 3 Proposal
    • 4 Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items

Contact

Florian Feick

Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com

Share Price

Data is delayed by 15 minutes.

Share Price Information

Related Links

Interactive Tool

Event

August 06, 2025 | Bad Homburg, Germany

Conference Call Q2 2025
Import (ICS)

FAQ

Shares and dividends
Parenteral nutrition using the veins.

Nutrition is a topic which is all around us, day by day. While we often talk about obesity and weight loss diets we actually overlook that the opposite, meaning mal- or undernutrition, can be as detrimental. We talk about malnutrition when our body is not provided with sufficient energy and nutrients over several days. These nutrients, for example protein, carbohydrates, fats, vitamins and minerals, are necessary to ensure all essential functions of the body.

When our nutritional status is not optimal our body will get w​eaker in its reaction towards challenges, such as a disease, a cold or an infection. Improving our nutritional status will therefore support and protect our body.

Enteral Nutrition

Every normal form of nutrition is actually enteral. The word, which comes from the Greek “enteron,” or intestines, means, “using the gastrointestinal tract.” Enteral nutrition therapies are designed for patients who cannot nourish themselves sufficiently but still have an adequate digestive function. It is therefore ideal for patients who experience problems chewing or swallowing, loss of appetite, suffer from neurological or gastro-intestinal diseases, or are unconscious. Enteral nutrition is administered via sip feeds or also tube feeds.

If you are not able to eat enough, sip feed nutrition can help to make up for this deficit. Sip feed nutrition can be taken by mouth, swallowed and digested like normal food. It is flavorful, liquid food and contains all nutrients such as carbohydrates, fats and fiber as well as vitamins, minerals and trace elements.
Sip feed nutrition is balanced. It contains all the nutrients required by a person. Therefore, it can be drunk or eaten in addition to normal food but is also suitable as a sole source of nutrition.

Tube feed nutrition can help you to meet your nutritional needs in times when you are not able to eat enough.
Tube feeding is a procedure used for administering liquid nutrition directly into the stomach or small intestine. To do this, a thin tube (probe) is inserted either through the nose (nasal probe) or through the abdomen into the stomach.

Parenteral Nutrition

Patients who are given Fresenius Kabi infusion solutions receive all the components of balanced nutrition: carbohydrates, amino acids and fats as well as minerals, vitamins and trace elements. The composition of these nutritional solutions can be precisely balanced to feed a patient for any period of time.

Parenteral nutrition is necessary when the stomach or intestine – for instance due to an illness or operation – can no longer perform their tasks. A doctor may also decide that a patient should receive parenteral nutrition prior to an operation or during lengthy examinations when he or she is not allowed to eat. In intravenous nutrition, all key nutrients enter the bloodstream as molecular components. A patient can rely on parenterally given nutrients for a long period of time.

There are a number of liquids with a variety of compositions that can be used for parenteral nutrition therapy either on their own or as a mixture. When deciding on the best nutritional therapy, the general condition of the patient plays an important role, as well as a patient’s age and weight. There are also solutions for patients with kidney or liver disease that contain a special composition of amino acids. Fresenius Kabi offers amino acids and carbohydrates as single components but also as a combination that contains both nutritional elements. Three-chamber bags contain all three important nutrients including fats.

Carbohydrates are the most important source of energy

Carbohydrates are the most important source of energy in parenteral nutrition. Often, glucose alone is sufficient. Glucose is a "universal fuel" that can be utilized by all the body’s cells, making it a standard nutrient for parenteral nutrition. Doctors can choose between solutions with different glucose concentrations. Combined solutions also contain other nutritional components besides carbohydrates.

Amino acids are essential for parenteral nutrition

Amino acids are the smallest components of proteins that perform many tasks in the body. Every organ requires proteins for its structure and function. Proteins transport, act as messengers, fight germs or control and create vital metabolic reactions. They are also important building blocks for muscles, hair and finger nails, for example.

All proteins consist of different amino acids. Therefore, amino acids are also indispensable for parenteral nutrition. Fresenius Kabi offers solutions containing amino acids in an ideal composition that the body can use to generate the required proteins.

Fats contain lots of energy and essential fatty acids

Fats contain not only a lot of energy, but also important fatty acids that the body itself cannot produce. These essential fatty acids help build up cell membranes and transmitters that regulate the metabolism.

Patients who are fed parenterally receive the fats as microscopic droplets that are suspended in a liquid known as emulsion. When this emulsion is infused into the blood stream, the tiny droplets disperse in the blood and can be absorbed by the body's cells. Fat emulsions help doctors to provide critically-ill patients with quickly-available energy while offering a reliable source of essential fatty acids.

Contact

Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
communication@fresenius-kabi.com

www.fresenius-kabi.com

Related Links

Fresenius Kabi Information page on the topics of malnutrition and sip feeds

Video

Explanatory video: Nutrition therapy

  • What happens when the normal intake of food is no longer possible?

Industrial production of infusion solutions at Fresenius Kabi's plant in Friedberg.

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients. 

Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition portfolio includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, Fresenius Kabi offers vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more. 

Following its “Vision 2026”, the company is furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. Fresenius Kabi aspires to be leading globally in its product segments – all for the benefit of patients, its customers, and its stakeholders.

Fresenius Kabi employs over 40,000 people worldwide. In 2024 the company reported sales of more than €8 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group and one of the two Operating Companies of Fresenius.

Contact

Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
communication@fresenius-kabi.com

Fresenius Kabi

Related Links

Infusion Therapy Clinical Nutrition Transfusion Technology

You will be now forwarded to the Fresenius Career page.

If the automatic redirect is not working, please click on the following link.

 

Fresenius Career

Home

FRESENIUS SE & CO. KGaA

 

 

 

News

  • Anke Schmidt appointed Head of Corporate Communications at Fresenius

    Anke Schmidt appointed Head of Corporate Communications at Fresenius

    Anke Schmidt (55) has been appointed Head of Corporate Communications at Fresenius, effective June 1, 2025. She will succeed Dennis Hofmann, who has headed the global communications function at Fresenius since September 2022 and has decided to leave the company on his own request to pursue new opportunities. Anke Schmidt will report directly to the CEO of Fresenius, Michael Sen. 

    May 27, 2025 · Fresenius

  • Brief News

    Denosumab CHMP Positive Opinion

    Fresenius announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for its denosumab biosimilar candidates for the treatment of osteoporosis and other bone-related conditions. The biosimilars are recommended for approval for all indications of the reference products 1Prolia® (denosumab) and 2Xgeva® (denosumab) from AMGEN. The CHMP positive opinion marks an important step in Fresenius Kabi's efforts to enhance patient access to biosimilar products and expand its capabilities and portfolio in biosimilars development. Developing the company's Biopharma platform is a key element of #FutureFresenius. 1Prolia® and 2Xgeva® are registered trademarks of Amgen Inc.

     

    May 27, 2025 · Fresenius Kabi

    2025 Annual General Meeting: Shareholders approve all agenda items

    2025 Annual General Meeting: Shareholders approve all agenda items

    May 23, 2025 · Fresenius

  • 2025 Annual General Meeting: Fresenius builds on strong momentum as it enters the Rejuvenate phase of #FutureFresenius

    2025 Annual General Meeting: Fresenius builds on strong momentum as it enters the Rejuvenate phase of #FutureFresenius

    The disciplined implementation of #FutureFresenius has made Fresenius a simpler, more focused, and stronger company. With the next phase, Rejuvenate, the focus in the years ahead will be on strengthening the core businesses, scaling platforms, and elevating performance. Dividend of 1.00 euro per share proposed. Thanks to the successful ongoing implementation of its #FutureFresenius strategy, Fresenius considers itself well-positioned to continue to deliver profitable growth and create long-term value. “With #FutureFresenius, the company has a coherent strategy that it will continue to implement consistently and successfully in the interests of all stakeholders. The Supervisory Board firmly believes that Fresenius fulfils all the requirements needed to achieve its ambitious goals. We support the course that the Management Board is pursuing. On behalf of the Supervisory Board, I thank the Management Board and all employees for their outstanding work,” said Wolfgang Kirsch, Chairman of the Supervisory Board, at this year’s Annual General Meeting (AGM) in Frankfurt am Main today. “The successful implementation of #FutureFresenius means Fresenius is now simpler, more focused, stronger, and more resilient. We are now in a better position to anticipate change more quickly and, if necessary, respond more effectively,” said Michael Sen, CEO of Fresenius. “Fresenius is essential to healthcare systems around the world – through our hospitals and our products, without which patient care would not be possible.” Furthermore, the company’s “Local for Local” strategy, focused on local value creation, manufacturing, and jobs, also strengthens its resilience. Fresenius began the year from a position of strength and launched the next phase of its #FutureFresenius strategy, Rejuvenate. Reducing the shares in Fresenius Medical Care in March this year was the first milestone. Fresenius used the proceeds to strengthen its balance sheet and further fuel innovation. Rejuvenate is about advancing and strengthening its core businesses. In addition, the company will scale up its three platforms – (Bio)Pharma, MedTech, and Care Provision – to unlock new long-term growth opportunities and achieve higher earnings. In the 2024 financial year, Fresenius once again increased the pace of growth in revenue and earnings. “Last year, we not only kept our promises but even exceeded our expectations and raised our guidance twice,” said Sen. The company achieved this through its efforts, to which all operating businesses contributed. Productivity also increased, and the self-imposed target corridor for the leverage ratio was achieved for the first time in seven years. By 2024, Fresenius had reduced its net debt by 2 billion euros and achieved an operating cash flow of 2.4 billion euros. A dividend of 1.00 euro per share was proposed for the past financial year during the Annual General Meeting. Fresenius also considers itself on track for 2025. “Our mission to save and improve human lives continues to drive us forward in the new financial year. With the next phase of #FutureFresenius, we want to continue our success story in 2025,” said Sen, referring to the strong start to the year. In early May, Fresenius confirmed its guidance for the full year 2025 following excellent growth in revenue and earnings during the first quarter. The AGM will be held in person, with several hundred shareholders attending this year’s event at Messe Frankfurt. * * * The letter by Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius, and the speech by Michael Sen, Chief Executive Officer of Fresenius, can be downloaded here: Annual General Meeting | FSE About Fresenius Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered n Bad Homburg v. d. Höhe, Germany. In the 2024 fiscal year, Fresenius generated €21.5 billion in annual revenue. Fresenius currently counts over 176,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in Fresenius Medical Care. With around 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects. For more information visit the Company’s website at www.fresenius.com Follow us on social media: www.fresenius.com/socialmedia

    May 23, 2025 · Fresenius

  • Brief News

    Fresenius expands its line of Epinephrine injectables in the U.S.

    Fresenius today announced that its operating company, Fresenius Kabi, is now offering Epinephrine Injection, USP, in 30 mg per 30 mL multi-dose vials in the United States. Following the introduction of the first generic version of Epinephrine, USP, in a 1 mg per mL vial for U.S. customers in December 2024, the product launch expands Fresenius’ offerings of Epinephrine Injection. Epinephrine Injection 30 mg per 30 mL is a prescription medicine used for emergency treatment of allergic reactions (Type 1), including anaphylaxis, in adults and pediatric patients and to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. In line with #FutureFresenius, Fresenius Kabi has invested more than $1 billion to expand and modernize advanced U.S. pharmaceutical production and distribution facilities. Epinephrine Injection is manufactured in the U.S., reflecting the company’s commitment to domestic production. More than 70% of the pharmaceuticals that Fresenius Kabi sells to U.S. customers are formulated, filled and packaged in the U.S.

     

    May 20, 2025 · Fresenius Kabi

    Visionary trailblazer: Fresenius and the Else Kröner-Fresenius Foundation celebrate 100 years of Else Kröner

    Visionary trailblazer: Fresenius and the Else Kröner-Fresenius Foundation celebrate 100 years of Else Kröner

    May 17, 2025 · Fresenius

  • Fresenius Q1/25: Strong start to 2025 – #FutureFresenius Rejuvenate phase kicked-off with excellent momentum

    Fresenius Q1/25: Strong start to 2025 – #FutureFresenius Rejuvenate phase kicked-off with excellent momentum

    Michael Sen, CEO of Fresenius: “We've kick-started 2025 with an excellent performance across the business and confirm our full-year guidance. Organic revenue increased by 7% driven by the consistent delivery of Fresenius Kabi and Fresenius Helios.

    May 07, 2025 · Fresenius

  • Brief News

    Fresenius makes progress on streamlining its production network

    Fresenius continues reducing complexity and optimizing utilization in the production network of its Operating Company Fresenius Kabi in line with its Vision 2026 and #FutureFresenius: Today, Fresenius Kabi and EMS have signed an agreement to transfer the ownership of Fresenius Kabi's production site in Anápolis, Brazil, to EMS. The multinational pharmaceutical company has a strong presence in Latin America and will take over the generic injectables production plant, the development center, and the warehouse as well as full staff and will continue production. The transaction is subject to customary closing conditions, including merger approval.

     

    April 09, 2025 · Fresenius Kabi

    Brief News

    Fresenius completes divestment of Vamed’s international project business

    Fresenius has completed the divestment of Vamed’s international project business to Worldwide Hospitals Group (WWH), that was announced in February 2025. The divestment is part of Fresenius’ structured exit from its Investment Company Vamed and enables Fresenius to further increase focus and management capacity on the ongoing progress of its core businesses Fresenius Kabi and Fresenius Helios, in line with #FutureFresenius.

     

    April 01, 2025 · Fresenius

  • Brief News

    Fresenius Receives FDA approval for their Denosumab Biosimilars and Secures Global Settlement

    Fresenius today announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence®** (denosumab-bnht) and Bomyntra®** (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the U.S. Food and Drug Administration (FDA). The denosumab biosimilars are approved for all indications of the reference products Prolia®* (denosumab) and Xgeva®* (denosumab), respectively. Additionally, Fresenius’ operating company has reached a global settlement with Amgen, allowing the launch of these biosimilars in the US from mid-2025 and in Europe later end of November 2025 subject to regulatory approval. The FDA approval and the global settlement agreement with Amgen are the latest developments in Fresenius’ continuing commitment to improving patient access to high-quality biological products through expanding its biosimilars development capabilities and product portfolio. Growing the company's (Bio)Pharma platform is a substantial cornerstone of #FutureFresenius. *Prolia® and Xgeva®* are registered trademarks of Amgen Inc. **Conexxence® and **Bomyntra® are registered trademarks of Fresenius Kabi Deutschland in selected countries. Read the full press release here. Please click to see full Prescribing Information for Conexxence®. Please click to see full Prescribing Information for Bomyntra®.

     

    March 26, 2025 · Fresenius Kabi

    Brief News

    Fresenius publishes 2024 Annual Report: #FutureFresenius makes the company more innovative, more focused and more efficient

    Today, Fresenius published its 2024 Annual Report. As already announced in February, the healthcare group grew profitably in the past year and achieved its outlook, which was raised twice, through consistently good business performance. Group revenue before special items increased to €21.5 billion, with organic growth of 8%. Fresenius was also able to reduce net debt by €2 billion in 2024. “Our #FutureFresenius program, which we launched at the end of 2022, is having an impact. The “new” Fresenius is much more focused. We are concentrating on Fresenius Kabi and Fresenius Helios. These are growing profitably and under their own steam,” said Michael Sen, Chairman of the Management Board of Fresenius. “Growth, higher margins, more cash, lower debt – all this has created value: From the beginning of October 2022, when we prepared the ReSet, until February 28, 2025, the share price rose by 76%.” For the first time, the Annual Report includes a sustainability report in accordance with the European Sustainability Reporting Standards (ESRS). This replaces the Non-financial Report of previous Annual Reports and expands and supplements reporting topics and details. In addition, the ESRS report, like the financial report, is audited externally. The 2024 Annual Report is available in German and English as a PDF file and as an online version. Further publication and event dates for 2025: · 04/24/2025: Publication of Sustainability Highlights Magazine · 05/07/2025: Publication of the financial results for Q1 2025 · 05/23/2025: Annual General Meeting · 08/06/2025: Publication of the financial results for Q2 2025 · 11/05/2025: Publication of the financial results for Q3 2025

     

    March 26, 2025 · Fresenius

  • Fresenius expands corporate headquarters in Bad Homburg with new innovation center

    Fresenius expands corporate headquarters in Bad Homburg with new innovation center

    March 17, 2025 · Fresenius

    Fresenius completes sale of shares in Fresenius Medical Care AG 

    Fresenius completes sale of shares in Fresenius Medical Care AG 

    March 04, 2025 · Fresenius

  • Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG to 25% plus one share 

    Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG to 25% plus one share 

    March 03, 2025 · Fresenius

    Brief News

    Continuing Biopharma Growth with U.S. and EU Launch of Ustekinumab Biosimilar

    Fresenius announced today that its Operating Company Fresenius Kabi’s ustekinumab biosimilar Otulfi® (ustekinumab-aauz), developed by Formycon AG, is now available in the United States and European Union. Otulfi® is an ustekinumab biosimilar for the reference product Stelara® (ustekinumab). In February 2023, Fresenius Kabi and Formycon entered a global commercialization partnership for the ustekinumab biosimilar covering key global markets. In September 2024, U.S. FDA and EC approval for both subcutaneous and intravenous formulations was received. Otulfi® is indicated for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis in the U.S. Being Fresenius’ fourth biosimilar on the market, the company continues the growth path of its BioPharma platform in line with #FutureFresenius.

     

    March 03, 2025 · Fresenius Kabi

  • Fresenius FY/24: Strong Fourth Quarter concludes successful Fiscal Year; Fresenius moving to next level of performance with #FutureFresenius Rejuvenate phase

    Fresenius FY/24: Strong Fourth Quarter concludes successful Fiscal Year; Fresenius moving to next level of performance with #FutureFresenius Rejuvenate phase

    February 26, 2025 · Fresenius

    Fresenius reaches agreement to exit Vamed’s international project business ahead of schedule

    Fresenius reaches agreement to exit Vamed’s international project business ahead of schedule

    February 03, 2025 · Fresenius

  • Brief News

    Fresenius Receives FDA 510(k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency

    Fresenius, via its operating company Fresenius Kabi, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Adaptive Nomogram, an alternate algorithm that will be available in the Aurora Xi Plasmapheresis System. The Adaptive Nomogram enables an average 11.6% increase in plasma collection per donation while maintaining safe and effective operation. This enhanced capability will allow plasma centers to improve collection efficiency. Plasma-derived therapies are essential for treating a wide range of conditions, including immune deficiencies, bleeding disorders, and neurological diseases. By increasing plasma collection efficiency, Fresenius Kabi reinforces its commitment to improving access to these critical therapies. The clearance received for the Adaptive Nomogram is another milestone in line with #FutureFresenius.

     

    January 28, 2025 · Fresenius Kabi

All News Disclaimer
Annual General Meeting 2025

May 23, 2025 - 10:00 am
Frankfurt, Germany

Annual General Meeting 2025

Information, Documents and Shareholder Online Service
Live-Webcast
Import (ICS)

Latest

#CommittedToLife

 

We save and improve human lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care.

Learn more about the Fresenius Group

Library

Fresenius Kabi has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines. The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.

Fresenius Kabi has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines. The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.

Ensure financial flexibility, maintain our investment grade rating, limit refinancing risks and optimize the cost of capital are the main objectives in Fresenius’s financing strategy.

To remain financially flexible, we maintain adequate liquidity headroom. We are committed to our investment grade rating, which provides us with advantages with respect to market access and funding costs.

Our refinancing risks are limited due to a balanced maturity profile that is characterized by a broad range of maturities with a high proportion of mid- and long-term debt up to 2033. Relevant financing instruments include bonds, Schuldschein Loans and bank loans. In addition, Fresenius maintains a commercial paper program. 

Another key objective of Fresenius’ financing strategy is to optimize the cost of capital by employing an adequate mix of equity and debt.

In 2025, deleveraging will remain a key priority. Fresenius has upgraded its leverage target corridor to 2.5 to 3.0x net debt/EBITDA (previously 3.5 to 3.0x). This allows us to stay financially flexible while solidifying our solid investment grade rating.
 

Fresenius Group

1 Prior-year figures have been adjusted due to the application of IFRS 5 to the deconsolidated operations of Fresenius Medical Care
2 Before special items
3 At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend; Net debt adjusted for valuation effect of equity-neutral exchangeable bond

Contact

Elisabeth Truckenbrodt

Director Investor Relations
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com

Share Price

Data is delayed by 15 minutes.

Share Price Information

Related Links

Interactive Tool

Library

General Credit Presentation (PDF, 1.62 MB)

Corporate Communications

Here you can find a variety of information:

   
Our Corporate Communications team can be reached at pr-fre@fresenius.com.

“A pharmacy today? We need to expand it or add something new to it.” (Dr. Eduard Fresenius, Founder, 1912)

Press Conference Full Year Results 2024

February 26, 2025 - 10:00 am
Bad Homburg, Germany

Press Conference Full Year Results 2024

Live Webcast
Press release Presentation Speech Michael Sen Speech Sara Hennicken Import (ICS)

Latest

News

  • Anke Schmidt appointed Head of Corporate Communications at Fresenius

    Anke Schmidt appointed Head of Corporate Communications at Fresenius

    Anke Schmidt (55) has been appointed Head of Corporate Communications at Fresenius, effective June 1, 2025. She will succeed Dennis Hofmann, who has headed the global communications function at Fresenius since September 2022 and has decided to leave the company on his own request to pursue new opportunities. Anke Schmidt will report directly to the CEO of Fresenius, Michael Sen. 

    May 27, 2025 · Fresenius

  • Brief News

    Denosumab CHMP Positive Opinion

    Fresenius announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for its denosumab biosimilar candidates for the treatment of osteoporosis and other bone-related conditions. The biosimilars are recommended for approval for all indications of the reference products 1Prolia® (denosumab) and 2Xgeva® (denosumab) from AMGEN. The CHMP positive opinion marks an important step in Fresenius Kabi's efforts to enhance patient access to biosimilar products and expand its capabilities and portfolio in biosimilars development. Developing the company's Biopharma platform is a key element of #FutureFresenius. 1Prolia® and 2Xgeva® are registered trademarks of Amgen Inc.

     

    May 27, 2025 · Fresenius Kabi

    2025 Annual General Meeting: Shareholders approve all agenda items

    2025 Annual General Meeting: Shareholders approve all agenda items

    May 23, 2025 · Fresenius

  • 2025 Annual General Meeting: Fresenius builds on strong momentum as it enters the Rejuvenate phase of #FutureFresenius

    2025 Annual General Meeting: Fresenius builds on strong momentum as it enters the Rejuvenate phase of #FutureFresenius

    The disciplined implementation of #FutureFresenius has made Fresenius a simpler, more focused, and stronger company. With the next phase, Rejuvenate, the focus in the years ahead will be on strengthening the core businesses, scaling platforms, and elevating performance. Dividend of 1.00 euro per share proposed. Thanks to the successful ongoing implementation of its #FutureFresenius strategy, Fresenius considers itself well-positioned to continue to deliver profitable growth and create long-term value. “With #FutureFresenius, the company has a coherent strategy that it will continue to implement consistently and successfully in the interests of all stakeholders. The Supervisory Board firmly believes that Fresenius fulfils all the requirements needed to achieve its ambitious goals. We support the course that the Management Board is pursuing. On behalf of the Supervisory Board, I thank the Management Board and all employees for their outstanding work,” said Wolfgang Kirsch, Chairman of the Supervisory Board, at this year’s Annual General Meeting (AGM) in Frankfurt am Main today. “The successful implementation of #FutureFresenius means Fresenius is now simpler, more focused, stronger, and more resilient. We are now in a better position to anticipate change more quickly and, if necessary, respond more effectively,” said Michael Sen, CEO of Fresenius. “Fresenius is essential to healthcare systems around the world – through our hospitals and our products, without which patient care would not be possible.” Furthermore, the company’s “Local for Local” strategy, focused on local value creation, manufacturing, and jobs, also strengthens its resilience. Fresenius began the year from a position of strength and launched the next phase of its #FutureFresenius strategy, Rejuvenate. Reducing the shares in Fresenius Medical Care in March this year was the first milestone. Fresenius used the proceeds to strengthen its balance sheet and further fuel innovation. Rejuvenate is about advancing and strengthening its core businesses. In addition, the company will scale up its three platforms – (Bio)Pharma, MedTech, and Care Provision – to unlock new long-term growth opportunities and achieve higher earnings. In the 2024 financial year, Fresenius once again increased the pace of growth in revenue and earnings. “Last year, we not only kept our promises but even exceeded our expectations and raised our guidance twice,” said Sen. The company achieved this through its efforts, to which all operating businesses contributed. Productivity also increased, and the self-imposed target corridor for the leverage ratio was achieved for the first time in seven years. By 2024, Fresenius had reduced its net debt by 2 billion euros and achieved an operating cash flow of 2.4 billion euros. A dividend of 1.00 euro per share was proposed for the past financial year during the Annual General Meeting. Fresenius also considers itself on track for 2025. “Our mission to save and improve human lives continues to drive us forward in the new financial year. With the next phase of #FutureFresenius, we want to continue our success story in 2025,” said Sen, referring to the strong start to the year. In early May, Fresenius confirmed its guidance for the full year 2025 following excellent growth in revenue and earnings during the first quarter. The AGM will be held in person, with several hundred shareholders attending this year’s event at Messe Frankfurt. * * * The letter by Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius, and the speech by Michael Sen, Chief Executive Officer of Fresenius, can be downloaded here: Annual General Meeting | FSE About Fresenius Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered n Bad Homburg v. d. Höhe, Germany. In the 2024 fiscal year, Fresenius generated €21.5 billion in annual revenue. Fresenius currently counts over 176,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in Fresenius Medical Care. With around 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects. For more information visit the Company’s website at www.fresenius.com Follow us on social media: www.fresenius.com/socialmedia

    May 23, 2025 · Fresenius

  • Brief News

    Fresenius expands its line of Epinephrine injectables in the U.S.

    Fresenius today announced that its operating company, Fresenius Kabi, is now offering Epinephrine Injection, USP, in 30 mg per 30 mL multi-dose vials in the United States. Following the introduction of the first generic version of Epinephrine, USP, in a 1 mg per mL vial for U.S. customers in December 2024, the product launch expands Fresenius’ offerings of Epinephrine Injection. Epinephrine Injection 30 mg per 30 mL is a prescription medicine used for emergency treatment of allergic reactions (Type 1), including anaphylaxis, in adults and pediatric patients and to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. In line with #FutureFresenius, Fresenius Kabi has invested more than $1 billion to expand and modernize advanced U.S. pharmaceutical production and distribution facilities. Epinephrine Injection is manufactured in the U.S., reflecting the company’s commitment to domestic production. More than 70% of the pharmaceuticals that Fresenius Kabi sells to U.S. customers are formulated, filled and packaged in the U.S.

     

    May 20, 2025 · Fresenius Kabi

    Visionary trailblazer: Fresenius and the Else Kröner-Fresenius Foundation celebrate 100 years of Else Kröner

    Visionary trailblazer: Fresenius and the Else Kröner-Fresenius Foundation celebrate 100 years of Else Kröner

    May 17, 2025 · Fresenius

  • Fresenius Q1/25: Strong start to 2025 – #FutureFresenius Rejuvenate phase kicked-off with excellent momentum

    Fresenius Q1/25: Strong start to 2025 – #FutureFresenius Rejuvenate phase kicked-off with excellent momentum

    Michael Sen, CEO of Fresenius: “We've kick-started 2025 with an excellent performance across the business and confirm our full-year guidance. Organic revenue increased by 7% driven by the consistent delivery of Fresenius Kabi and Fresenius Helios.

    May 07, 2025 · Fresenius

  • Brief News

    Fresenius makes progress on streamlining its production network

    Fresenius continues reducing complexity and optimizing utilization in the production network of its Operating Company Fresenius Kabi in line with its Vision 2026 and #FutureFresenius: Today, Fresenius Kabi and EMS have signed an agreement to transfer the ownership of Fresenius Kabi's production site in Anápolis, Brazil, to EMS. The multinational pharmaceutical company has a strong presence in Latin America and will take over the generic injectables production plant, the development center, and the warehouse as well as full staff and will continue production. The transaction is subject to customary closing conditions, including merger approval.

     

    April 09, 2025 · Fresenius Kabi

    Brief News

    Fresenius completes divestment of Vamed’s international project business

    Fresenius has completed the divestment of Vamed’s international project business to Worldwide Hospitals Group (WWH), that was announced in February 2025. The divestment is part of Fresenius’ structured exit from its Investment Company Vamed and enables Fresenius to further increase focus and management capacity on the ongoing progress of its core businesses Fresenius Kabi and Fresenius Helios, in line with #FutureFresenius.

     

    April 01, 2025 · Fresenius

  • Brief News

    Fresenius Receives FDA approval for their Denosumab Biosimilars and Secures Global Settlement

    Fresenius today announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence®** (denosumab-bnht) and Bomyntra®** (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the U.S. Food and Drug Administration (FDA). The denosumab biosimilars are approved for all indications of the reference products Prolia®* (denosumab) and Xgeva®* (denosumab), respectively. Additionally, Fresenius’ operating company has reached a global settlement with Amgen, allowing the launch of these biosimilars in the US from mid-2025 and in Europe later end of November 2025 subject to regulatory approval. The FDA approval and the global settlement agreement with Amgen are the latest developments in Fresenius’ continuing commitment to improving patient access to high-quality biological products through expanding its biosimilars development capabilities and product portfolio. Growing the company's (Bio)Pharma platform is a substantial cornerstone of #FutureFresenius. *Prolia® and Xgeva®* are registered trademarks of Amgen Inc. **Conexxence® and **Bomyntra® are registered trademarks of Fresenius Kabi Deutschland in selected countries. Read the full press release here. Please click to see full Prescribing Information for Conexxence®. Please click to see full Prescribing Information for Bomyntra®.

     

    March 26, 2025 · Fresenius Kabi

    Brief News

    Fresenius publishes 2024 Annual Report: #FutureFresenius makes the company more innovative, more focused and more efficient

    Today, Fresenius published its 2024 Annual Report. As already announced in February, the healthcare group grew profitably in the past year and achieved its outlook, which was raised twice, through consistently good business performance. Group revenue before special items increased to €21.5 billion, with organic growth of 8%. Fresenius was also able to reduce net debt by €2 billion in 2024. “Our #FutureFresenius program, which we launched at the end of 2022, is having an impact. The “new” Fresenius is much more focused. We are concentrating on Fresenius Kabi and Fresenius Helios. These are growing profitably and under their own steam,” said Michael Sen, Chairman of the Management Board of Fresenius. “Growth, higher margins, more cash, lower debt – all this has created value: From the beginning of October 2022, when we prepared the ReSet, until February 28, 2025, the share price rose by 76%.” For the first time, the Annual Report includes a sustainability report in accordance with the European Sustainability Reporting Standards (ESRS). This replaces the Non-financial Report of previous Annual Reports and expands and supplements reporting topics and details. In addition, the ESRS report, like the financial report, is audited externally. The 2024 Annual Report is available in German and English as a PDF file and as an online version. Further publication and event dates for 2025: · 04/24/2025: Publication of Sustainability Highlights Magazine · 05/07/2025: Publication of the financial results for Q1 2025 · 05/23/2025: Annual General Meeting · 08/06/2025: Publication of the financial results for Q2 2025 · 11/05/2025: Publication of the financial results for Q3 2025

     

    March 26, 2025 · Fresenius

  • Fresenius expands corporate headquarters in Bad Homburg with new innovation center

    Fresenius expands corporate headquarters in Bad Homburg with new innovation center

    March 17, 2025 · Fresenius

    Fresenius completes sale of shares in Fresenius Medical Care AG 

    Fresenius completes sale of shares in Fresenius Medical Care AG 

    March 04, 2025 · Fresenius

  • Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG to 25% plus one share 

    Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG to 25% plus one share 

    March 03, 2025 · Fresenius

    Brief News

    Continuing Biopharma Growth with U.S. and EU Launch of Ustekinumab Biosimilar

    Fresenius announced today that its Operating Company Fresenius Kabi’s ustekinumab biosimilar Otulfi® (ustekinumab-aauz), developed by Formycon AG, is now available in the United States and European Union. Otulfi® is an ustekinumab biosimilar for the reference product Stelara® (ustekinumab). In February 2023, Fresenius Kabi and Formycon entered a global commercialization partnership for the ustekinumab biosimilar covering key global markets. In September 2024, U.S. FDA and EC approval for both subcutaneous and intravenous formulations was received. Otulfi® is indicated for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis in the U.S. Being Fresenius’ fourth biosimilar on the market, the company continues the growth path of its BioPharma platform in line with #FutureFresenius.

     

    March 03, 2025 · Fresenius Kabi

  • Fresenius FY/24: Strong Fourth Quarter concludes successful Fiscal Year; Fresenius moving to next level of performance with #FutureFresenius Rejuvenate phase

    Fresenius FY/24: Strong Fourth Quarter concludes successful Fiscal Year; Fresenius moving to next level of performance with #FutureFresenius Rejuvenate phase

    February 26, 2025 · Fresenius

    Fresenius reaches agreement to exit Vamed’s international project business ahead of schedule

    Fresenius reaches agreement to exit Vamed’s international project business ahead of schedule

    February 03, 2025 · Fresenius

  • Brief News

    Fresenius Receives FDA 510(k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency

    Fresenius, via its operating company Fresenius Kabi, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Adaptive Nomogram, an alternate algorithm that will be available in the Aurora Xi Plasmapheresis System. The Adaptive Nomogram enables an average 11.6% increase in plasma collection per donation while maintaining safe and effective operation. This enhanced capability will allow plasma centers to improve collection efficiency. Plasma-derived therapies are essential for treating a wide range of conditions, including immune deficiencies, bleeding disorders, and neurological diseases. By increasing plasma collection efficiency, Fresenius Kabi reinforces its commitment to improving access to these critical therapies. The clearance received for the Adaptive Nomogram is another milestone in line with #FutureFresenius.

     

    January 28, 2025 · Fresenius Kabi

All News Disclaimer
Captcha
Image CAPTCHA
Get new captcha!
Enter the characters shown in the image.
Operating room at a HELIOS clinic

Fresenius Helios is one of the largest and most medically-advanced operators of both in- and outpatient care in Europe, offering expertise in all areas of clinical care. 

Fresenius Helios owns and operates Helios hospitals in Germany and Quirónsalud hospitals in Spain and Latin America. Every year more than 24 million patients choose Helios for medical treatment, of whom 22.2 million are outpatients. Fresenius Helios is committed to the highest quality clinical and nursing care.

 

Helios

Based in Berlin, Helios owns and operates 87 clinics, including seven maximum care hospitals in Erfurt, Berlin-Buch, Duisburg, Wuppertal, Schwerin, Krefeld and Wiesbaden. Helios hospitals provide inpatient care to about 1.2 million patients annually.

As the only hospital group in Germany Helios operates its own hospitals ranging from basic care starting at 46 beds to maximum care with 1,500 beds. The acute care hospitals offer nearly the full spectrum of medical services at a high level of quality. Some Helios clinics are renowned beyond Germany’s borders for their outstanding medical achievements.

By combining senior citizens’ homes and acute medical care, Helios gives residents access to optimum, fast medical care. Helios has already implemented this intelligent and trend-setting concept of short distances for seniors at nine of its hospitals.

Helios strives to expand its integrated medical care offering. This is made possible through cooperations with non-hospital providers, especially local doctors’ practices, as well as our own medical care centers close to the hospitals. Our medical care centers are only established where they offer a useful complement to our hospitals and when high-quality outpatient care cannot be guaranteed over a long period through cooperations with local doctors’ practices. In medical care centers, patients are treated before or after an inpatient hospital stay. An important goal is to avoid unnecessary duplication in examinations, because high quality and competent medical care in conjunction with the rational use of resources best serves the well-being of patients.

Quironsalud

Quirónsalud operates 57 hospitals, 100 outpatient centers and around 300 occupational risk prevention centers. Active in every major metropolitan region of Spain, and now with seven hospitals in Latin America, Madrid-based Quirónsalud has more than 49,000 employees.


 

360° Panorama laden

Extreme concentration and the most modern medical technology: Here you can take a look around the operating room as Peter Horn, M.D., PhD, Head of Neurosurgery at Helios Hospital Dr. Horst Schmidt Kliniken, successfully removes a 4-centimeter (1.6-inch) tumor from a patient’s brain.

Contact

Helios Kliniken GmbH
Friedrichstr. 136
10117 Berlin
Germany
T +49 30 521 321-0

www.helios-gesundheit.de

Contact

Grupo Hospitalario Quirónsalud
C\ Zurbarán 28
28010 Madrid
Spain

www.quironsalud.es

Related Links

Fresenius Helios A day on the Neonatology A robot at the operating table

Video

The Healthcare of Tomorrow

 The healthcare of the future will be ever more digitalized, networked and specialized.

Subscribe to